Sanofi has agreed to hand $462 million to Regeneron for an early wrap to their immuno-oncology alliance, narrowly limiting an R&D relationship that will now concentrate on 2 lead programs in the clinic and leaving each of the companies free to pursue their own fates in I/O as they move to begin shuttering one of the industry’s most productive development alliances.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription